Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.
Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab ... The companies said this is the first time a medicine has shown a clinical benefit in basal cell carcinoma ...
Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in melanoma ...